ArticleEFSA journal. European Food Safety Authority2018
Re-evaluation of silicon dioxide (E 551) as a food additive.
Article in EFSA journal. European Food Safety Authority, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed.
- Silica Nanoparticles from Sustainable Sources: Fundamentals of Processing and Emerging Strategies.Gels (Basel, Switzerland) · 2026Review
- In Vitro Evaluation of Silica-Coated BiACS omega · 2026Article
- Comparative Evaluation of Glidants for Enhancing the Flowability of Poorly Flowing Powdered Materials with Varying Particle Sizes and Morphologies.Pharmaceutics · 2026Article
- Edible optical microcavities for optical barcoding, authentication, and sensing.Scientific reports · 2026Article
- Food-derived β-lactoglobulin nanofibrils: An efficacy, safe, and scalable solution to overcome oral insulin delivery challenges.Bioactive materials · 2026Article
- Article
- Health Risk Assessment of Dietary Chemical Exposures: A Comprehensive Review.Foods (Basel, Switzerland) · 2025Review
- Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.Molecular cancer · 2025Review
- Orally ingested nanosilica causes liver-specific accumulation and induces liver senescence and fibrosis via the microbiota-gut-liver axis.Journal of nanobiotechnology · 2025Article
- Diatomaceous Earth Supplementation as a Bioavailable Silicon Source Modulates Postprandial Lipid Metabolism in Healthy Female Rats.Nutrients · 2025Article
- Impact of Milk on the Behavior and Toxicity of Nanosized SiOACS omega · 2025Article
- Mitigating Aflatoxin BProbiotics and antimicrobial proteins · 2025Article
- Pickering Double Emulsions Stabilized with Chitin Nanocrystals and Myristic Acid-Functionalized Silica Nanoparticles for Curcumin and Chlorogenic Acid Co-Delivery.Pharmaceutics · 2025Article
- Silicon Dioxide Nanoparticles Affect the In Vitro Digestion of Sodium Caseinate but Not the Formation and Functionality of Bioactive Peptides.Food science & nutrition · 2025Article
- Silicon-Based Nanomaterials in Chronic Wound Healing: Mechanisms, Therapeutic Applications, and Clinical Prospects.International journal of nanomedicine · 2025Review
- Oral Toxicity Study of Silicon Dioxide Nanoparticles on Fertility and Early Embryonic Development in Mice.International journal of nanomedicine · 2025Article
- Microbial conversion of vegetable waste for flavor additives via solid-state fermentation: a comprehensive review.Frontiers in nutrition · 2025Review
- Impact of metallic nanoparticles on gut microbiota modulation in colorectal cancer: A review.Cancer innovation · 2024Review
- DNA-Based Chemical Unclonable Functions for Cryptographic Anticounterfeit Tagging of Pharmaceuticals.ACS nano · 2024Article
- Comparative Assessment of Cellular Responses to Microscale Silica Morphologies in Human Gastrointestinal Cells: Insights for Occupational Health.International journal of environmental research and public health · 2024Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion re-evaluating the safety of silicon dioxide (E 551) when used as a food additive. The forms of synthetic amorphous silica (SAS) used as E 551 include fumed silica and hydrated silica (precipitated silica, silica gel and hydrous silica). The Scientific Committee on Food (SCF) established a group acceptable daily intake (ADI) 'not specified' for silicon dioxide and silicates. SAS materials used in the available biological and toxicological studies were different in their physicochemical properties; their characteristics were not always described in sufficient detail. Silicon dioxide appears to be poorly absorbed. However, silicon-containing material (in some cases presumed to be silicon dioxide) was found in some tissues. Despite the limitations in the subchronic, reproductive and developmental toxicological studies, including studies with nano silicon dioxide, there was no indication of adverse effects. E 551 does not raise a concern with respect to genotoxicity. In the absence of a long-term study with nano silicon dioxide, the Panel could not extrapolate the results from the available chronic study with a material, which does not cover the full-size range of the nanoparticles that could be present in the food additive E 551, to a material complying with the current specifications for E 551. These specifications do not exclude the presence of nanoparticles. The highest exposure estimates were at least one order of magnitude lower than the no observed adverse effect levels (NOAELs) identified (the highest doses tested). The Panel concluded that the EU specifications are insufficient to adequately characterise the food additive E 551. Clear characterisation of particle size distribution is required. Based on the available database, there was no indication for toxicity of E 551 at the reported uses and use levels. Because of the limitations in the available database, the Panel was unable to confirm the current ADI 'not specified'. The Panel recommended some modifications of the EU specifications for E 551.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.